Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa

Tomomitsu Tahara, Tomoyuki Shibata, Masakatsu Nakamura, Hiromi Yamashita, Daisuke Yoshioka, Masaaki Okubo, Naoko Maruyama, Toshiaki Kamano, Yoshio Kamiya, Hiroshi Fujita, Mitsuo Nagasaka, Masami Iwata, Kazuya Takahama, Makoto Watanabe, Ichiro Hirata, Tomiyasu Arisawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

There have been reports showing a protective role of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) against gastrointestinal cancers. E-cadherin (CDH1) is an adhesion molecule involved in tumour invasion/metastasis. Silencing of CDH1 by promoter CpG island methylation was shown in gastric cancer, precancerous lesion, and Helicobacter pylori-infected chronic gastritis. We investigated the methylation status of CDH1 in noncancerous gastric mucosa in chronic aspirin user, and assessed its effect on methylation-associated carcinogenesis. Gastric mucosa samples from antrum were obtained from 217 cancer-free subjects, including 37 chronic aspirin users and 180 subjects with no history of chronic or occasional intake of aspirin. Methylation-specific polymerase chain reaction (PCR), i.e., MSP, was performed for CDH1 gene promoter. In all 217 subjects, CDH1 methylation was detected for 69 subjects (31.7%). CDH1 methylation more frequently occurred in H. pylori-infection-positive subjects (P < 0.0001), while chronic aspirin users had a significantly lower risk of CDH1 methylation [nonuser versus user 36.1% versus 10.8%; odds ratio (OR) = 0.21, 95% confidence interval (CI) = 0.07-0.63, P = 0.005]. Logistic regression analysis showed that chronic aspirin use was the independent factor for lower risk of CDH1 methylation (adjusted OR = 0.21, 95%CI = 0.07-0.66, P = 0.008). Chronic aspirin use was associated with lower risk of CDH1 methylation in H. pylori-positive subjects (nonuser versus user 49.5% versus 19.0%; OR = 0.24, 95%CI = 0.08-0.76, P = 0.01). Similar trend was also found in H. pylori-negative subjects (P = 0.07). No association was found between CDH1 methylation status, and duration and dose of aspirin. Our data suggest that chronic aspirin use is associated with reduced risk of CDH1 methylation in human gastric mucosa. Aspirin may have suppressive role against methylation-related gastric carcinogenesis.

Original languageEnglish
Pages (from-to)54-59
Number of pages6
JournalDigestive Diseases and Sciences
Volume55
Issue number1
DOIs
Publication statusPublished - 01-01-2010

Fingerprint

Gastric Mucosa
Methylation
Aspirin
Helicobacter pylori
Odds Ratio
Confidence Intervals
Carcinogenesis
CpG Islands
Gastrointestinal Neoplasms
Helicobacter Infections
Gastritis
Cadherins
Stomach Neoplasms
Neoplasms
Stomach
Anti-Inflammatory Agents
Logistic Models
Regression Analysis
Neoplasm Metastasis
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Tahara, T., Shibata, T., Nakamura, M., Yamashita, H., Yoshioka, D., Okubo, M., ... Arisawa, T. (2010). Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. Digestive Diseases and Sciences, 55(1), 54-59. https://doi.org/10.1007/s10620-008-0701-4
Tahara, Tomomitsu ; Shibata, Tomoyuki ; Nakamura, Masakatsu ; Yamashita, Hiromi ; Yoshioka, Daisuke ; Okubo, Masaaki ; Maruyama, Naoko ; Kamano, Toshiaki ; Kamiya, Yoshio ; Fujita, Hiroshi ; Nagasaka, Mitsuo ; Iwata, Masami ; Takahama, Kazuya ; Watanabe, Makoto ; Hirata, Ichiro ; Arisawa, Tomiyasu. / Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. In: Digestive Diseases and Sciences. 2010 ; Vol. 55, No. 1. pp. 54-59.
@article{2df5a6bb96ee4bdd9f0cf358efd020ab,
title = "Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa",
abstract = "There have been reports showing a protective role of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) against gastrointestinal cancers. E-cadherin (CDH1) is an adhesion molecule involved in tumour invasion/metastasis. Silencing of CDH1 by promoter CpG island methylation was shown in gastric cancer, precancerous lesion, and Helicobacter pylori-infected chronic gastritis. We investigated the methylation status of CDH1 in noncancerous gastric mucosa in chronic aspirin user, and assessed its effect on methylation-associated carcinogenesis. Gastric mucosa samples from antrum were obtained from 217 cancer-free subjects, including 37 chronic aspirin users and 180 subjects with no history of chronic or occasional intake of aspirin. Methylation-specific polymerase chain reaction (PCR), i.e., MSP, was performed for CDH1 gene promoter. In all 217 subjects, CDH1 methylation was detected for 69 subjects (31.7{\%}). CDH1 methylation more frequently occurred in H. pylori-infection-positive subjects (P < 0.0001), while chronic aspirin users had a significantly lower risk of CDH1 methylation [nonuser versus user 36.1{\%} versus 10.8{\%}; odds ratio (OR) = 0.21, 95{\%} confidence interval (CI) = 0.07-0.63, P = 0.005]. Logistic regression analysis showed that chronic aspirin use was the independent factor for lower risk of CDH1 methylation (adjusted OR = 0.21, 95{\%}CI = 0.07-0.66, P = 0.008). Chronic aspirin use was associated with lower risk of CDH1 methylation in H. pylori-positive subjects (nonuser versus user 49.5{\%} versus 19.0{\%}; OR = 0.24, 95{\%}CI = 0.08-0.76, P = 0.01). Similar trend was also found in H. pylori-negative subjects (P = 0.07). No association was found between CDH1 methylation status, and duration and dose of aspirin. Our data suggest that chronic aspirin use is associated with reduced risk of CDH1 methylation in human gastric mucosa. Aspirin may have suppressive role against methylation-related gastric carcinogenesis.",
author = "Tomomitsu Tahara and Tomoyuki Shibata and Masakatsu Nakamura and Hiromi Yamashita and Daisuke Yoshioka and Masaaki Okubo and Naoko Maruyama and Toshiaki Kamano and Yoshio Kamiya and Hiroshi Fujita and Mitsuo Nagasaka and Masami Iwata and Kazuya Takahama and Makoto Watanabe and Ichiro Hirata and Tomiyasu Arisawa",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/s10620-008-0701-4",
language = "English",
volume = "55",
pages = "54--59",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "1",

}

Tahara, T, Shibata, T, Nakamura, M, Yamashita, H, Yoshioka, D, Okubo, M, Maruyama, N, Kamano, T, Kamiya, Y, Fujita, H, Nagasaka, M, Iwata, M, Takahama, K, Watanabe, M, Hirata, I & Arisawa, T 2010, 'Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa', Digestive Diseases and Sciences, vol. 55, no. 1, pp. 54-59. https://doi.org/10.1007/s10620-008-0701-4

Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. / Tahara, Tomomitsu; Shibata, Tomoyuki; Nakamura, Masakatsu; Yamashita, Hiromi; Yoshioka, Daisuke; Okubo, Masaaki; Maruyama, Naoko; Kamano, Toshiaki; Kamiya, Yoshio; Fujita, Hiroshi; Nagasaka, Mitsuo; Iwata, Masami; Takahama, Kazuya; Watanabe, Makoto; Hirata, Ichiro; Arisawa, Tomiyasu.

In: Digestive Diseases and Sciences, Vol. 55, No. 1, 01.01.2010, p. 54-59.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa

AU - Tahara, Tomomitsu

AU - Shibata, Tomoyuki

AU - Nakamura, Masakatsu

AU - Yamashita, Hiromi

AU - Yoshioka, Daisuke

AU - Okubo, Masaaki

AU - Maruyama, Naoko

AU - Kamano, Toshiaki

AU - Kamiya, Yoshio

AU - Fujita, Hiroshi

AU - Nagasaka, Mitsuo

AU - Iwata, Masami

AU - Takahama, Kazuya

AU - Watanabe, Makoto

AU - Hirata, Ichiro

AU - Arisawa, Tomiyasu

PY - 2010/1/1

Y1 - 2010/1/1

N2 - There have been reports showing a protective role of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) against gastrointestinal cancers. E-cadherin (CDH1) is an adhesion molecule involved in tumour invasion/metastasis. Silencing of CDH1 by promoter CpG island methylation was shown in gastric cancer, precancerous lesion, and Helicobacter pylori-infected chronic gastritis. We investigated the methylation status of CDH1 in noncancerous gastric mucosa in chronic aspirin user, and assessed its effect on methylation-associated carcinogenesis. Gastric mucosa samples from antrum were obtained from 217 cancer-free subjects, including 37 chronic aspirin users and 180 subjects with no history of chronic or occasional intake of aspirin. Methylation-specific polymerase chain reaction (PCR), i.e., MSP, was performed for CDH1 gene promoter. In all 217 subjects, CDH1 methylation was detected for 69 subjects (31.7%). CDH1 methylation more frequently occurred in H. pylori-infection-positive subjects (P < 0.0001), while chronic aspirin users had a significantly lower risk of CDH1 methylation [nonuser versus user 36.1% versus 10.8%; odds ratio (OR) = 0.21, 95% confidence interval (CI) = 0.07-0.63, P = 0.005]. Logistic regression analysis showed that chronic aspirin use was the independent factor for lower risk of CDH1 methylation (adjusted OR = 0.21, 95%CI = 0.07-0.66, P = 0.008). Chronic aspirin use was associated with lower risk of CDH1 methylation in H. pylori-positive subjects (nonuser versus user 49.5% versus 19.0%; OR = 0.24, 95%CI = 0.08-0.76, P = 0.01). Similar trend was also found in H. pylori-negative subjects (P = 0.07). No association was found between CDH1 methylation status, and duration and dose of aspirin. Our data suggest that chronic aspirin use is associated with reduced risk of CDH1 methylation in human gastric mucosa. Aspirin may have suppressive role against methylation-related gastric carcinogenesis.

AB - There have been reports showing a protective role of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) against gastrointestinal cancers. E-cadherin (CDH1) is an adhesion molecule involved in tumour invasion/metastasis. Silencing of CDH1 by promoter CpG island methylation was shown in gastric cancer, precancerous lesion, and Helicobacter pylori-infected chronic gastritis. We investigated the methylation status of CDH1 in noncancerous gastric mucosa in chronic aspirin user, and assessed its effect on methylation-associated carcinogenesis. Gastric mucosa samples from antrum were obtained from 217 cancer-free subjects, including 37 chronic aspirin users and 180 subjects with no history of chronic or occasional intake of aspirin. Methylation-specific polymerase chain reaction (PCR), i.e., MSP, was performed for CDH1 gene promoter. In all 217 subjects, CDH1 methylation was detected for 69 subjects (31.7%). CDH1 methylation more frequently occurred in H. pylori-infection-positive subjects (P < 0.0001), while chronic aspirin users had a significantly lower risk of CDH1 methylation [nonuser versus user 36.1% versus 10.8%; odds ratio (OR) = 0.21, 95% confidence interval (CI) = 0.07-0.63, P = 0.005]. Logistic regression analysis showed that chronic aspirin use was the independent factor for lower risk of CDH1 methylation (adjusted OR = 0.21, 95%CI = 0.07-0.66, P = 0.008). Chronic aspirin use was associated with lower risk of CDH1 methylation in H. pylori-positive subjects (nonuser versus user 49.5% versus 19.0%; OR = 0.24, 95%CI = 0.08-0.76, P = 0.01). Similar trend was also found in H. pylori-negative subjects (P = 0.07). No association was found between CDH1 methylation status, and duration and dose of aspirin. Our data suggest that chronic aspirin use is associated with reduced risk of CDH1 methylation in human gastric mucosa. Aspirin may have suppressive role against methylation-related gastric carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=74049109327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049109327&partnerID=8YFLogxK

U2 - 10.1007/s10620-008-0701-4

DO - 10.1007/s10620-008-0701-4

M3 - Article

VL - 55

SP - 54

EP - 59

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 1

ER -